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Obesity-induced inflammation originating from ex-
panding adipose tissue interferes with insulin sensi-
tivity. Importantmetabolic effects have been recently
attributed to IL-1b and IL-18, two members of the
IL-1 family of cytokines. Processing of IL-1b and
IL-18 requires cleavage by caspase-1, a cysteine
protease regulated by a protein complex called the
inflammasome. We demonstrate that the inflamma-
some/caspase-1 governs adipocyte differentiation
and insulin sensitivity. Caspase-1 is upregulated
during adipocyte differentiation and directs adipo-
cytes toward a more insulin-resistant phenotype.
Treatment of differentiating adipocytes with re-
combinant IL-1b and IL-18, or blocking their effects
by inhibitors, reveals that the effects of caspase-1
on adipocyte differentiation are largely conveyed by
IL-1b. Caspase-1 and IL-1b activity in adipose tissue
is increased both in diet-induced and genetically
induced obese animal models. Conversely, mice
deficient in caspase-1 are more insulin sensitive as
compared to wild-type animals. In addition, differen-
tiation of preadipocytes isolated from caspase-1/
or NLRP3/ mice resulted in more metabolically
active fat cells. In vivo, treatment of obese mice
with a caspase-1 inhibitor significantly increases
their insulin sensitivity. Indirect calorimetry analysis
revealed higher fat oxidation rates in caspase-1/
animals. In conclusion, the inflammasome is anCell Mimportant regulator of adipocyte function and insulin
sensitivity, and caspase-1 inhibition may represent
a novel therapeutic target in clinical conditions asso-
ciated with obesity and insulin resistance.
INTRODUCTION
The prevalence of obesity, an important risk factor for type 2
diabetes, hypertension, and hyperlipidemia, has reached
epidemic proportions worldwide (Mokdad et al., 2001). Initially
viewed as a tissue that merely stores energy, recently it has
become evident that adipose tissue also releases hormone-like
mediators named adipokines, and exerts effects reminiscent of
an endocrine organ (Lago et al., 2007). During the development
of obesity, the morphology and functional properties of adipose
tissue change dramatically. In addition to adipocyte hypertrophy
due to storage of increasing amounts of lipids, adipose tissue
turns into an inflamed tissue characterized by macrophage infil-
tration and altered secretion of adipokines (Hotamisligil, 2006;
Weisberg et al., 2003).Whereas the secretion of proinflammatory
cytokines is enhanced, the production of insulin-sensitizing
adipokines such as adiponectin is reduced. To date, many proin-
flammatory cytokines have been linked to the development of
insulin resistance and type 2 diabetes, including TNFa and IL-6
(Hotamisligil, 2006; Guilherme et al., 2008). More recently,
interest has grown into the role of the IL-1 family of cytokines
and its prominent members IL-1b and IL-18. IL-1b is a proinflam-
matory cytokine with a role in the pathogenesis of type 1 dia-
betes through its toxic effects on b cells of the pancreas
(Ohara-Imaizumi et al., 2004). It has been shown that treatment
of type 2 diabetic patients with IL-1Ra, an antagonist of IL-1etabolism 12, 593–605, December 1, 2010 ª2010 Elsevier Inc. 593
Figure 1. Caspase-1 Is Activated during Adipogenesis In Vitro and Is Present in Adipocytes of Mouse and Human White Adipose Tissue
In Vivo
(A) Quantitative PCR analysis of differentiating human or mouse adipocytes. Representative results are shown of n = 3 experiments.
(B) Western blot analysis of caspase-1 protein levels in differentiating mouse 3T3-L1 adipocytes and human SGBS adipocytes. Protein marker is given in kDalton.
(C) Caspase-1 activity in preadipocytes (Pre) and adipocytes at day 8 of differentiation (Mature).
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et al., 2007). Recent work has also revealed an important role
of IL-18 in modulation of energy balance and insulin sensitivity
(Netea et al., 2006).
In order to be activated, IL-1b and IL-18 have to be processed
from inactive precursors by an intracellular cysteine protease
called caspase-1 (Petrilli et al., 2007; Wilmanski et al., 2008).
Activation of caspase-1 itself takes place by conformational
changes in a protein platform called the inflammasome, consist-
ing of caspase-1 and proteins of the NACHT-LRR (NLR) family
including NLRP3 and ASC, leading to the release of the active
enzyme (Kanneganti et al., 2007). The inflammasome is activated
in response to so-called danger-associated molecular patterns,
which can be elicited either by microbial components (e.g.,
peptidoglycan) or by endogenous danger signals (e.g., uric
acid, ATP) (Petrilli et al., 2007). Because of the metabolic effects
described for IL-1b and IL-18, and due to the crucial role of
caspase-1 for the activation of these cytokines, we hypothesized
that inflammasome-dependent activation of caspase-1 plays an
important role in the metabolic function of the adipose tissue.
This hypothesis was tested using a number of in vitro and
in vivo approaches.
RESULTS
Expression and Function of Caspase-1 in Adipocytes
To explore the role of the caspase-1 in adipocyte function, we
first assessed the expression of caspase-1 during in vitro adipo-
genesis. Interestingly, differentiation of mouse 3T3-L1, human
Simpson-Golabi-Behmel syndrome (SGBS), and human primary
adipocytes was associated with a significant increase in expres-
sion of caspase-1 in parallel with the adipogenic transcription
factor PPARg (Figure 1A). IL-1b gene expression levels during
adipocyte differentiation displayed a more variable pattern
(Figure 1B).
Caspase-1 protein levels were significantly higher in differen-
tiated cells (Figure 1B), and caspase-1 activity levels were
increased in fully differentiated adipocytes versus preadipocytes
(Figure 1C). In order to assess whether caspase-1 influences
adipocyte differentiation, we blocked caspase-1 with the cas-
pase-1 inhibitor Pralnacasan (Rudolphi et al., 2003). This inhib-
itor more effectively reduced caspase-1 activity compared to
the frequently used caspase-1 inhibitor Yvad, as determined
by an in vitro caspase-1 activity assay (see Figure S1A available
online). Caspase-1 blockade improved expression levels of adi-
pogenic marker genes including PPARg, adiponectin, and Glut4
gene expression (Figure 1D). Importantly, caspase-1 blockage in
human adipose tissue using Pralnacasan reduced the secretion
of IL-1b (Figure S1B). In addition to caspase-1 inhibition using
an inhibitor, caspase-1 function was silenced using siRNA.
Treatment of cells with siRNA targeted to caspase-1 led to
a significant reduction in caspase-1 gene expression (relative(D) Quantitative PCR analysis of SGBS adipocytes differentiated for 12 days in t
(E) Quantitative PCR analysis and representative oil red O staining of SGBS adipo
IL-1ra (5 mg/ml), anti-IL-1b antibody (5 mg/ml), or IL-18 (25 ng/ml).
(F) Western blot analysis of caspase-1 in total human and mouse white adipose
(G) Caspase-1 expression in the stromal vascular cells and mature adipocytes fra
Asterisks depict statistically significant differences between control and experim
Cell Mgene expression levels, 1.00 ± 0.04 versus 0.16 ± 0.01). In
addition to mRNA levels, caspase-1 protein levels were
decreased in cells transected with siRNA targeted against
caspase-1 (Figure S2A). Basal secretion levels of bioactive
IL-1, as measured by using the murine thymoma cell line EL4/
NOB 1 that produces IL-2 in response to bioactive IL-1, were
unchanged in cells depleted of caspase-1. Probably, levels of
IL-1 produced by the cells under normal conditions are relatively
low, and the secreted IL-1 may directly bind to the cell
membrane. Silencing of caspase-1 in SGBS adipocytes
improved insulin sensitivity as determined by pAKT/AKT ratios
after short-term insulin treatment (mock versus siRNA cas-
pase-1, 0.95 ± 0.14 versus 2.10 ± 0.16; p value < 0.005). Finally,
treatment of caspase-1-depleted cells with recombinant IL-1b
led to a reduction in pAKT levels (Figure S2B).
To examine whether the effects of caspase-1 may be medi-
ated by processing of IL-1b or IL-18, we studied the effects
of these cytokines on adipocyte differentiation. Whereas re-
combinant IL-1b blocked adipogenesis, as assessed by oil red
O staining, recombinant IL-18 had no affect (Figure 1E). Impor-
tantly, treatment of differentiating adipocytes with recombinant
IL-1 receptor antagonist to block endogenous IL-1 signaling
mirrored the effects of caspase-1 inhibition (Figure 1E). More-
over, specific blockage of IL-1b-signaling pathways in differenti-
ating SGBS adipocytes using an anti-IL-1b antibody also re-
sulted in an improvement of adipogenesis (Figure 1E). Thus,
effects of caspase-1 on adipogenesis are likely conveyed via
endogenous IL-1b. In order to confirm that caspase-1 has a func-
tional role in vivo, caspase-1 protein levels were assessed in
human andmousewhite adipose tissue. Both human andmouse
white adipose tissue displayed total (45 kDA) and activated
caspase-1 isoforms (34 kDA) (Figure 1F). Fractioning of total
human and mouse white adipose tissue into mature adipocytes
and stromal vascular cells revealed that caspase-1 is expressed
in both cell populations (Figure 1G). Taken together, our data
show that caspase-1 is upregulated during in vitro adipocyte
differentiation and is present in mouse and human white adipose
tissue in vivo.
Caspase-1 Function in Experimental Models of Obesity
To determine caspase-1 function in adipose tissue during
diet-induced obesity, C57Bl/6 mice were fed a high-fat diet
(HFD) for 16 weeks. HFD feeding caused obesity, as illustrated
by increased bodyweight (Figure 2A) and epididymal adipose
tissue mass (Figure 2B). Importantly, after prolonged HFD,
adipose tissue expression of caspase-1 wasmarkedly increased
(Figure 2C). A similar increase in caspase-1 mRNA and protein
was observed in obese db/db mice and ob/ob mice (Figure 2D).
Protein levels of the active isoform of caspase-1 (34 kDA) were
increased in white adipose tissue of obese animals (Figure 2E).
Noticeably, specificity of the antibody used to detect caspase-1
protein levelswas testedbyusing adipose tissueofwild-type andhe presence of the specific caspase-1 inhibitor Pralnacasan at 100 mM.
cytes differentiated for 7 days in the presence of recombinant IL-1b (10 ng/ml),
tissue. Protein marker is given in kDalton.
ctionated from total white adipose tissue. Data are presented as mean ± SEM.
ental groups. *p < 0.05, **p < 0.005.
etabolism 12, 593–605, December 1, 2010 ª2010 Elsevier Inc. 595
Figure 2. Caspase-1 Is Activated in Adipocytes of Diet-Induced and Genetically Induced Obese Animals
(A) Bodyweight development in male wild-type C57/bl6 animals (2 months of age at start of intervention) fed either a LFD or HFD (n = 10 per group).
(B) Percent of epidydimal white adipose tissue after 17 weeks of HFD feeding.
(C) Quantitative PCR analysis of caspase-1 gene expression in white adipose tissue of C57/Bl6 animals during dietary intervention (n = 6 per group).
(D) White adipose tissue of wild-type, db/db, and ob/ob animals (4 months of age) is analyzed for caspase-1 gene expression levels using quantitative PCR
analysis (n = 5 per group).
(E) Western blot analysis of caspase-1 in white adipose tissue of WT and db/db animals. Actin levels are shown as loading control.
(F) Caspase-1 activity levels measured in total white adipose tissue of LFD- or HFD-fed animals and ob/ob mice.
(G) IL-1b and IL-18 concentrations (pg/ml) measured in total white adipose tissue of WT animals fed a LFD or HFD and IL-1b concentrations (pg/ml) present in
white adipose tissue of WT and db/db mice (n = 5 per group).
(H) Gene expression levels of CD68 and caspase-1 in white adipose tissue of wild-type animals (2 months of age at start of intervention) fed a LFD or a HFD for
16 weeks and a HFD followed by intraperitoneal injection with clodronate liposomes. Data are presented as mean ± SEM. Asterisks depict statistically significant
differences between control and experimental groups. *p < 0.05, **p < 0.005, ***p < 0.001.
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expression and protein levels, caspase-1 activity was also
increased in total white adipose tissue of HFD and ob/ob animals
compared to lean mice (Figure 2F). The increased caspase-1
activity was accompanied by significantly elevated IL-1b and
IL-18 protein levels in adipose tissue of diet-induced and genet-
ically induced obese mice (Figure 2G). Although IL-1b and IL-18
protein levels were elevated, we were unable to detect any
significant changes in gene expression of IL-1b and IL-18 in total
adipose tissue of obese versus lean animals.
Previous studies have shown that obesity and adipocyte
hypertrophy result in an influx of macrophages into adipose
tissue (Weisberg et al., 2003; Xu et al., 2003), and we assessed
whether the increased expression of caspase-1 in adipose tissue
was due to an increase in the infiltrating macrophages or the
adipocytes themselves. Partial depletion of macrophages from
adipose tissue of animals fed a HFD decreased the expression
of themacrophagemarker CD68, yet did not alter the expression
of caspase-1 (Figure 2H), suggesting that caspase-1 effects on
adipose tissue are not only exerted through infiltrating macro-
phages. Together, these data show that both diet-induced and
genetically induced obesity result in activation of caspase-1
and increased levels of IL-1b and IL-18 in adipose tissue.
Caspase-1 Modulates Adipocyte Function
To assess in more detail the role of caspase-1 in adipocyte
function, preadipocytes from caspase-1-deficient mice and
wild-type mice were differentiated toward adipocytes using
a standard adipocyte differentiation protocol. In the absence of
caspase-1, adipogenesis was enhanced, as illustrated by oil
red O staining (Figure 3A) and increased gene expression levels
of GLUT-4, adiponectin, and PPARg (Figure 3B). Importantly,
secretion of adiponectin, a key regulator of insulin sensitivity
(Kadowaki et al., 2006), was significantly elevated in cas-
pase-1-deficient adipocytes (Figure 3C). Additionally, insulin
signaling in caspase-1-deficient adipocytes was ameliorated,
as visualized by an increased phosphorylation of Akt (Figure 3D)
(relative pAKT/AKT ratio, WT 10 nm insulin versus caspase-1/
10 nm insulin, 1 ± 0.53 versus 3.09 ± 0.12, p value < 0.05; WT
100 nm insulin versus caspase-1/ 100 nm insulin, 4.13 ±
1.33 versus 8.85 ± 1.8, p value < 0.05). Importantly, in mature
human adipocytes made insulin resistant by overnight treatment
with 200 nM of insulin, caspase-1 inhibition increased insulin
action as determined by pAKT levels after 20 min of insulin treat-
ment (50 nM) (Figure 3E) (relative pAKT/AKT ratio, control versus
inhibitor, 1 ± 0.24 versus 2.41 ± 0.15, p value < 0.01).
Because NLRP3 is an important component of the inflamma-
some involved in the activation of caspase-1 (Petrilli et al.,
2007), we investigated whether absence of NLRP3 mimics the
effects seen in caspase-1-deficient animals. Adipocyte differenti-
ation of preadipocytes isolated from NLRP3-deficient animals
was similarly enhanced compared to caspase-1-deficient cells
(Figures 3F and 3G). Finally, we tested insulin sensitivity of total
whiteadipose inwild-type,caspase-1/, andNLRP3/ animals.
As shown in Figure 3H, the absence of caspase-1 and NLRP3
in white adipose tissue resulted in an increase in adipose
tissue insulin sensitivity as determined by phosphorylation of
AKT (relative pAKT/AKT ratio, WT versus caspase-1/ versus
NALP3/, 10 nM insulin, 4.06 ± 0.54 versus 11.20 ± 1.66 versusCell M12.11 ± 2.19, p value < 0.05; 100 nm insulin, 5.56 ± 0.43 versus
14.47 ± 2.88 versus 29.23 ± 7.28, p value < 0.05) . In line with
the rise in insulin sensitivity, IL-1b production of adipose tissue
isolated from caspase-1/ and NLRP3/ animals was signifi-
cantly reduced as compared to white adipose tissue from wild-
type mice (Figure 3I). These data establish an important function
of caspase-1 and NLRP3 in adipocyte formation and insulin
sensitivity.
Absence of Caspase-1 Improves Insulin Sensitivity
In Vivo
To unveil the potential role of caspase-1 in vivo, adipose tissue
function and morphology were analyzed in caspase-1-deficient
animals. The absence of caspase-1 led to a profound change
in adipose tissue morphology (Figure 4A) with markedly smaller
adipocytes (average adipocyte size, WT mice 966.8 mM2, cas-
pase-1/mice 629.16 mM2, p value < 0.001) (Figure 4A). In addi-
tion, although total bodyweight was not different between both
genotypes (Figure 4B), DEXA scan analysis of caspase-1/
animals revealed a profound reduction in total fat mass
(Figure 4B). On the other hand, bone mineral content was signif-
icantly elevated in caspase-1/ animals compared to wild-type
mice (Figure 4B).
In linewith thebeneficial change in adipose tissuemorphology,
gene expression analysis revealed elevated levels of PPARg,
adiponectin, and GLUT4, consistent with increased insulin
sensitivity and improved glucose uptake in adipose tissue (Fig-
ure 4C). In addition, adiposePGC1a andPGC1bgene expression
levels were highly elevated in caspase-1-deficient animals
(Figure 4C), implying an increase in mitochondrial activity and
energy expenditure (Handschin and Spiegelman, 2006). Indeed,
quantification of mitochondrial DNA content in WAT of wild-type
and caspase-1/ animals revealed a robust increase in mtDNA
of white adipose tissue in the absence of caspase-1 (Figure 4D).
Finally, our in vitro observations showing enhanced insulin
action in caspase-1-deficient adipocytes were accompanied by
an improvement in total insulin sensitivity in caspase-1-deficient
animals, as illustrated by a decrease in basal plasma insulin
levels and lower plasma glucose levels during insulin tolerance
tests (Figures4Eand4F).Assessmentofwhole-body insulin resis-
tance by euglycemic hyperinsulinemic clamp analysis revealed
a significant improvement of insulin sensitivity in caspase-1/
animals as compared to wild-type mice (Figure 4G, Figure S4A,
Table S1). Furthermore, both basal and hyperinsulinemic FFA
concentrations were significantly lower in caspase-1/ mice
compared to control mice (basal, 0.69 ± 0.06 versus 0.89 ±
0.04, p value = 0.001; hyperinsulinemic, 0.30 ± 0.02 versus 0.41 ±
0.04, p value=0.01), consistentwitha reduction in lipolytic activity
and an increase in insulin sensitivity of white adipose tissue in the
absenceof caspase-1.Other basal plasma lipids including triglyc-
erides and cholesterol were not altered in caspase-1-deficient
animals (data not shown). Since caspase-1 controls IL-1b activity,
insulin tolerance was also analyzed in IL-1b-deficient animals.
Insulin sensitivity was improved in IL-1b-deficient animals when
compared to wild-type mice (Figure 4G). Finally, in line with the
important role of NLRP3 in the activation of caspase-1,NLRP3/
animals were more insulin sensitive compared to wild-type ani-
mals (Figure 4H). Noticeably, adipose tissue morphology in IL-1-
and NLRP3-deficient animals was unchanged. Nevertheless,etabolism 12, 593–605, December 1, 2010 ª2010 Elsevier Inc. 597
Figure 3. Absence of Caspase-1 and NLRP3 Improves Adipogenesis and Insulin Sensitivity in Differentiated Adipocytes
(A) Representative oil red O staining pictures and quantification of WT and caspase-1-deficient preadipocytes differentiated toward adipocytes for 7 days.
(B) GLUT4, adiponectin, and PPARg gene expression levels as determined by quantitative real-time PCR in preadipocytes (Pre) or differentiated adipocytes
(Induction) from WT or caspase-1-deficient animals.
(C) Adiponectin concentrations (pg/ml) measured in medium of preadipocytes (Pre) or adipocytes (Induction) differentiated for 7 days from WT or
caspase-1-deficient animals.
(D) Western blot analysis of phosphorylated AKT and total AKT levels after insulin treatment for 20 min in adipocytes differentiated for 7 days.
(E) Western blot analysis of phosphorylated AKT and total AKT levels after 20 min of insulin treatment in mature SGBS adipocytes pretreated overnight with
200 nM of insulin and/or the caspase-1 inhibitor pralnacasan (100 mM).
(F) Representative oil red O staining pictures and quantification of WT and NLRP3-deficient preadipocytes differentiated toward adipocytes for 7 days.
(G) GLUT4, Adiponectin, and PPARg gene expression levels in preadipocytes (Pre) or differentiated adipocytes (Induction) fromWT or NALP3-deficient animals.
(H) Western blot analysis of phosphorylated AKT and total AKT levels in white adipose tissue explants from wild-type, caspase-1/, and NLRP3/ animals
(2 months of age) after 20 min of insulin treatment.
(I) IL-1b production of adipose tissue explants from WT, caspase-1/, and NLRP3/ animals after 24 hr of culturing. Data are presented as mean ± SEM.
Asterisks depict statistically significant differences between control and experimental groups. *p < 0.05, **p < 0.005.
Cell Metabolism
Inflammasome, Obesity, and Insulin Resistance
598 Cell Metabolism 12, 593–605, December 1, 2010 ª2010 Elsevier Inc.
Figure 4. Caspase-1 Contributes to Adipose Tissue Formation and Function In Vivo
(A) Representative HE staining of white adipose tissue and quantification of adipocyte size.
(B) Total bodyweight, percentage of fat mass, and bone mineral content of WT and caspase-1/ mice (6 months of age).
(C) Gene expression analysis of total white adipose of WT and caspase-1-deficient mice using real-time quantitative PCR techniques.
(D) mtDNA content of total white adipose tissue from WT and caspase-1/ animals.
(E) Plasma insulin levels in nonfasted WT and caspase-1-deficient animals (n = 9 per group).
(F) Insulin tolerance test in WT and caspase-1-deficient animals (n = 9 per group).
(G) Assessment of whole-body insulin resistance by euglycemic hyperinsulinemic clamp analysis in wild-type (n = 17) and caspase-1/ (n = 18) animals at 1 year
of age. Glucose infusion rates (GIR) during the euglycemic hyperinsulinemic clamp analysis are shown.
(H) Insulin tolerance test in WT and IL-1b-deficient animals (n = 5 per group).
(I) Insulin tolerance test in WT and NALP3-deficient animals (n = 5 per group). Data are presented as mean ± SEM. Asterisks depict statistically significant
differences between control and experimental groups. *p < 0.05, **p < 0.005, ***p < 0.001.
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althoughdifferenceswere not statistically significant (FigureS4B).
Caspase-1 Inhibition during Obesity Improves Insulin
Sensitivity
The involvement of caspase-1 in the modulation of insulin resis-
tance renders it an attractive therapeutic target in clinical condi-
tions such as type 2 diabetes. In order to provide the proof of
principle that caspase-1 inhibition can improve insulin sensitivity,
ob/ob mice were treated with a chemical inhibitor of caspase-1
activity. Animals orally received 200 mg/kg bodyweight
caspase-1 inhibitor (Pralnacasan) or vehicle daily for 2 weeks.
After 2 weeks of treatment, insulin tolerance tests were per-
formed. Animals treated with the caspase-1 inhibitor showed
a robust improvement of insulin sensitivity as compared to
animals receiving vehicle only (Figure 5A). The effectiveness of
caspase-1 inhibition was analyzed by measuring IL-1b protein
levels in white adipose tissue. As expected, caspase-1 inhibition
led to a significant reduction of IL-1b protein concentration in fat
(Figure 5B). Noticeably, treatment of ob/ob animals with pralna-
casan did not result in changes in fecal fat content or physical
activity levels of the animals.
Interestingly, the improvement of insulin sensitivity was
accompanied by an attenuated increase in bodyweight in
animals receiving the caspase-1 inhibitor (Figure 5C), despite
a similar daily food intake (Figure 5D). The percentage of
epidydimal white adipose tissue in ob/ob animals receiving the
inhibitor tended to be lower as compared to animals receiving
vehicle only (p value = 0.06), suggestive of changes in lipid
storage and lipogenesis in white adipose tissue (Figure 5E).
Because lipid composition may be involved in the effects of
caspase-1 on adipose tissue, the general lipid composition of
the white adipose tissue was analyzed. As shown in Figure 5F,
the amounts of C16:0 (palmitic acid) and C18:0 (stearic acid)
present in white adipose tissue were significantly higher in
animals receiving the inhibitor, whereas the concentration of
C18:1 (oleic acid) was lower. Finally, the ratios of C16:1/C16:0
and C18:1/C18:0, indicative of desaturation through SCD-1
activity, were lower in ob/ob animals treated with the inhibitor
(Figure 5G), suggestive of a decrease in lipogenesis.
Inasmuch as no changes were observed in the ratios of C18:0/
C16:0 and C16:1/C18:1 (data not shown), elongase activity
appeared to be unchanged. Noticeably, fatty acid composition
and ratios of C18:1/C18:0 and C16:1/C16:0 in plasma samples
were unchanged. Plasma FFA levels were unchanged in ob/ob
animals fed the inhibitor as compared to the control animals
(0.18 mM ± 0.04 versus 0.18 mM ± 0.009).
The effect of caspase-1 on the development of obesity and
insulin resistance was analyzed using a diet intervention. Ten
weeks of HFD feeding led to significantly less bodyweight gain
in caspase-1/ mice as compared to HFD-fed wild-type
animals (Figure 5H), despite a similar food intake (Figure 5I).
Moreover, insulin sensitivity as measured by an ITT test was
significantly higher in caspase-1/ animals compared to wild-
type mice fed the HFD (Figure 5J).
Absence of Caspase-1 Increases Fat Oxidation Rate
Inasmuch as the inhibition of caspase-1 attenuates bodyweight
gain despite a similar food intake, caspase-1/ and C57Bl/6600 Cell Metabolism 12, 593–605, December 1, 2010 ª2010 Elsevierwild-type mice were subjected to indirect calorimetry analysis
using metabolic cages to determine their energy expenditure.
Food intake and respiratory gas exchange was measured at
7 min intervals for a period of 60 hr. Respiratory gas exchange
was calculated from oxygen consumption and carbon dioxide
production and analyzed separately for diurnal and nocturnal
periods to distinguish between periods of low (diurnal) and
high (nocturnal) physical activity.
In line with our previous results, food intake was similar
in both groups (wild-type, 4.99 ± 0.26 g/day; caspase-1/,
4.62 ± 0.15 g/day; p value = 0.3). Fecal output (wild-type, 1.4 ±
0.07 g/day; caspase-1/, 1.4 ± 0.07 g/day; p value = 0.9) as
well as fecal fat content (steatocrit percent, WT, 7.13 ± 0.38;
caspase-1/, 8.02 ± 0.49; p value = 0.17) were not different
between both genotypes.
Total energy expenditure did not differ between groups during
the nocturnal period (WT, 0.54 ± 0.03 kcal/hr; caspase-1/,
0.62 ± 0.03 kcal/h; p value = 0.06), nor the diurnal period
(WT, 0.45 ± 0.02 kcal/hr; caspase-1/, 0.45 ± 0.02 kcal/hr;
p value = 0.9). Interestingly, diurnal RER values were sig-
nificantly lower in caspase-1/ animals (WT, 0.919 ± 0.012;
caspase-1/, 0.885 ± 0.006) (Figure 6A). The lower RER values
were translated into a higher absolute fat oxidation rate
during the diurnal part of the day (WT, 0.09 ± 0.01 kcal/hr;
caspase-1/, 0.13 ± 0.01 kcal/hr; p value = 0.02) (Figure 6B).
Nocturnal relative and absolute fat oxidation rates as well as total
diurnal and nocturnal carbohydrate oxidation rates did not differ
between groups (Figures 6B and 6C). Together, these data indi-
cate that caspase-1/ animals have higher fat oxidation rates
compared to controls, while food intake and fecal output were
equal between groups.
DISCUSSION
In the present study we demonstrate that during differentiation
and lipid accumulation, adipose tissue undergoes important
proinflammatory changes represented by inflammasome and
caspase-1 activation. These changes lead to a higher level of
IL-1b production and contribute to the induction of insulin
resistance.
The importance of inflammation and infiltration of macro-
phages in the modulation of adipose tissue function and insulin
resistance has been intensively studied over the last years
(Hotamisligil, 2006; Weisberg et al., 2003). IL-1b has been
previously linked to obesity-induced inflammation and the devel-
opment of insulin resistance in adipose tissue (Jager et al., 2007;
Lagathu et al., 2006). Our results demonstrate that caspase-1
activation in adipose tissue of obese animals takes place partly
independent of macrophage infiltration, induces the release of
IL-1b, and finally results in the development of insulin resistance
through autocrine and paracrine effects. In the absence of
caspase-1, adipocytes differentiate more efficiently and are
more sensitive to insulin. We observed similar effects in the
absence of the inflammasome component NLRP3 that has
been previously demonstrated to mediate caspase-1 activation
(Petrilli et al., 2007). In addition to robust changes in adipose
tissue morphology, we also suggest that the absence of
caspase-1 results in an increased mitochondrial energy dissipa-
tion reflected by an increase in PGC-1a and PGC-1b geneInc.
Figure 5. Caspase-1 Blockage Improves Insulin Sensitivity
(A) Insulin tolerance test in male ob/ob animals (2 months of age at start of intervention) orally treated with a chemical caspase-1 inhibitor (Pralnacasan) or vehicle
for 2 weeks (n = 5 per group).
(B) IL-1b concentrations (pg/ml) measured in total white adipose tissue of ob/ob mice receiving vehicle or a caspase-1 inhibitor (n = 5 per group).
(C) Bodyweight change (in %) during oral treatment of ob/ob animals with vehicle or a caspase-1 inhibitor (n = 5 per group).
(D) Food intake (kcal/day) of ob/ob animals orally treated with a chemical caspase-1 inhibitor or vehicle for 2 weeks.
(E) Percentage of epididymal white adipose tissue.
(F) Lipid composition of white adipose tissue.
(G) Desaturation indexes in vehicle or caspase-1 inhibitor-treated animals.
(H) Bodyweight development of WT or caspase-1/ animals (2 months of age at start of intervention) fed a LFD or HFD for 10 weeks (n = 10 per group).
(I) Food intake (kcal/day) of WT or caspase-1/ fed a LFD or HFD.
(J) Insulin tolerance test in WT and caspase-1/ animals fed a HFD for 10 weeks (n = 5 per group). Data are presented as mean ± SEM. Asterisks depict
statistically significant differences between control and experimental groups.*p < 0.05, **p < 0.005.
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Figure 6. Absence of Caspase-1 Augments Fat
Oxidation Rate
(A) Respiratory exchange rates, (B) fat oxidation, and (C)
carbohydrate oxidation levels in WT and caspase-1/
animals. Black and white bars represent mean nocturnal
and diurnal data ± SEM, respectively. Asterisk indicates
p < 0.05.
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adipose tissue. Expression levels of PGC-1a and -b in
caspase-1-deficient animals are probably increased due to the
absence of bioactive IL-1b (Kim et al., 2007). Assessment of
additional metabolic parameters of caspase-1/ animals
revealed that, although total caloric expenditure as well as
food intake and fecal output did not differ between groups,
absolute fat oxidation rateswere higher in caspase-1/ animals.
Whereas fat oxidation comprised 20% of the total amount of
diurnal caloric expenditure in wild-type animals, it contributed
up to 30% in the caspase-1/ animals. Ultimately, this results
in a less positive fat balance and can explain the reduction in
fat mass observed in caspase-1/ animals.
In addition to activation of IL-1b, caspase-1 also cleaves pro-
IL-18 to its bioactive form. In line with activation of caspase-1 in
adipose tissue, IL-18 protein levels were increased in adipose
tissue of HFD-fed animals compared to mice fed the LFD.
However, our in vitro data show that the effects of IL-18 on
adipocyte differentiation and gene expression are minor as
compared to IL-1b. In addition, it has been previously shown
that aging IL-18/ animals develop obesity and insulin resis-
tance (Netea et al., 2006). Overall this suggests that, although
IL-1b and IL-18 both serve as substrates of caspase-1, the
effects of these cytokines on adipocyte function and insulin
sensitivity appear to be opposite, and the absence of IL-1b
masks the effects of IL-18.
Importantly, we show that caspase-1-deficient animals are
more insulin sensitive, which strongly supports the concept of
the involvement of the inflammasome/caspase-1 pathway in
the development of insulin resistance associated with obesity.
Additionally, we demonstrate that blockage of caspase-1 in
obese and insulin-resistant animals results in an improvement
of insulin sensitivity and a smaller increase in total bodyweight.
This reduction in weight gain is also reflected by a lower adipose
tissue mass in animals receiving the caspase-1 inhibitor. The
relatively small reduction in adipose tissue mass in animals
receiving the inhibitor may be partly explained by the limited
treatment period. Longer treatment of the animals with a
caspase-1 inhibitor might lead to more pronounced differences
in adipose tissue mass. In addition to the quantitative changes,
we also observed qualitative changes in adipose tissue compo-
sition, illustrated by a significantly lower desaturation in white
adipose tissue of animals treated with the inhibitor. This
suggests that SCD-1 activity that catalyzes the synthesis of
monounsaturated fatty acids is lower after caspase-1 inhibition.
Since SCD-1/ animals have a reduction in adiposity due to
enhanced lipid oxidation together with an improvement in insulin
sensitivity (Ntambi et al., 2002), regulation of SCD-1 activity by
caspase-1 in adipose tissuemay partly explain our observations.602 Cell Metabolism 12, 593–605, December 1, 2010 ª2010 ElsevierInasmuch as SREBPs, which partly control SCD-1 activity, are
processed and activated by caspase-1 (Gurcel et al., 2006), it
may explain the reduction in desaturation index in adipose tissue
of ob/ob animals after caspase-1 inhibition.
Hypothetically, the absence of caspase-1 in adipose tissue
leads toanenhancedadipogenesisparalleledbyan improvement
in lipid oxidation due to enhanced mitochondrial function. The
stimulation of adipogenesis in caspase-1/ animals might
primarily prevent lipidaccumulation in non-fat tissues. In addition,
it is unlikely that caspase-1 activation in adipose tissue will solely
lead to IL-1b and IL-18production, since it has been reported that
caspase-1 is able to cleave additional substrates (Lamkanfi et al.,
2008a). Adipocyte-specific proteinsmayalso serve as caspase-1
substrates leading to functional changes in adipose tissue of
obese animals. Interestingly, it has been shown that caspase-1
is able to cleave and inactivate PPARg in adipocytes (He et al.,
2008) that may also contribute to the detrimental effects of
caspase-1 activation in adipose tissue of obese animals. Further-
more, adipose tissue-independent effects of caspase-1may also
contribute to the development of obesity-induced insulin resis-
tance. Future studies are needed to resolve this issue and will
shedmore light on themechanisms responsible for the resistance
to diet-induced obesity in caspase-1/ animals.
Beneficial effects of IL-1 blockade by the natural antagonist
IL-1Ra have been recently reported in type 2 diabetes patients
(Larsen et al., 2007), and our data provide the rationale for
proposing caspase-1 inhibition as a potential novel therapeutic
target in conditions associated with obesity and/or insulin
resistance.
One important question that remains to be answered regards
the precise mechanisms leading to caspase-1 activation during
accumulation of fat in the adipocytes. It is still conceivable that
the influx of macrophages might influence the activation of
adipocyte-specific caspase-1, although our in vitro experiments
showing caspase-1 activation in adipocytes in settings free of
inflammatory cells suggest that adipocytes represent an impor-
tant source of caspase-1. Nevertheless, our results do not rule
out crosstalk between adipocyte-specific caspase-1 and
production of IL-1b by macrophages in adipose tissue. Alterna-
tively, lipids themselves or other mediators encountered in the
obese patient (e.g., adipokines) could induce activation of
caspase-1. Finally, glycemic conditions might induce caspase-1
activation in adipose tissue. Interestingly, hyperglycemic condi-
tions have been shown to activate NLRP3 in pancreatic cells,
and a similar mechanism may exist in adipose tissue (Zhou
et al., 2010). Unraveling these molecular mechanisms is one of
the important challenges for the near future.
In conclusion, our data reveal a novel metabolic function of the
inflammasome/caspase-1 in adipose tissue. An increase in fatInc.
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counteracts the normal metabolic function of adipose tissue
leading to insulin resistance. Inhibition of caspase-1 in obese
and insulin-resistant animals strongly improves insulin sensitivity
together with changes in adipose tissue mass and composition.
Importantly, the absence of caspase-1 results in an enhance-
ment of overall fat oxidation rates. These findings suggest that
pharmacological inhibition of caspase-1 in obese and/or
patients with type 2 diabetes may restore the metabolic function
of adipose tissue and subsequently improve insulin sensitivity.
EXPERIMENTAL PROCEDURES
Animal Studies
IL-1b/ mice were a gift from J. Mudgett, Merck Research Laboratories,
Rahway, USA. Caspase-1/ mice were a kind gift from Prof. Dinarello,
Department of Medicine, University of Colorado Health Sciences Center,
Denver, CO 80262, USA. NLRP3/ mice were generated as described
previously (Kanneganti et al., 2006). All mice were backcrossed ten genera-
tions to C57Bl/6 mice, and age-matched wild-type C57Bl/6J mice were
used as controls throughout the different experiments. Db/db and ob/ob
mice in a C57Bl/6 background were obtained from the Jackson Laboratories.
Diet Intervention
Wild-type C57Bl/6J male mice received a LFD or a HFD for 16 weeks,
providing 10% or 45% energy percent in the form of triglycerides (D12450B
or D12451, Research Diets, New Brunswick, USA). In the last week of dietary
intervention, some animals were injected intraperitoneally with clodronate
liposomes. The liposomeswere prepared as described previously (van Rooijen
and Sanders, 1994) using phosphatidylcholine (Lipoid GmbH, Ludwigshafen,
Germany) and cholesterol (Sigma Chem.Co. USA). Cl2MDP (or clodronate)
was a gift of Roche Diagnostics GmbH, Mannheim, Germany. Caspase-1/
and wild-type mice were fed the similar LFD or HFD during 10 weeks.
Insulin-tolerance tests were performed as previously described (Miyake
et al., 2002). Briefly, animals were fasted for 4 hr and insulin was given intraper-
itoneally at a dose of 0.75 U/kg bodyweight. Blood samples were taken before
and 30, 60, 90, or 120 min after insulin administration. Plasma levels of insulin
and adiponectin secretion in cell culture medium were measured using ELISA
(LINCO Research Inc., St. Charles, MO, USA).
Euglycemic Hyperinsulinemic Clamp Analysis
Euglycemic hyperinsulinemic clamps were performed as described earlier
(Voshol et al., 2001). Briefly, after an overnight fast, animals were anesthetized
with 6.25 mg/kg acepromazine (Sanofi Sante´ Nutrition Animale, Libourne
Cedex, France), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands),
and 312.5 mg/kg fentanyl (Janssen-Cilag, Tilburg, the Netherlands), and an
infusion needle was placed in the tail vein. A bolus of insulin (3 mU) was given,
and a hyperinsulinemic euglycemic clamp was started with a continuous
infusion of insulin (5 mU/h) and a variable infusion of 12.5% D-glucose (in
PBS) to maintain blood glucose level at euglycemic levels. Blood samples
were taken every 5–10 min from the tip of the tail to monitor plasma glucose
levels (AccuCheck). Seventy, eighty, and ninety minutes after the start of the
clamp, blood samples (70 ml) were taken for determination of plasma glucose,
insulin, and FFA concentrations. Plasma glucose, insulin, and FFA levels were
determined using commercially available kits (Instruchemie; Crystal Chem,
Inc.; and Wako Pure Chemical Industries, respectively).
Indirect Calorimetry
Animals were housed in a controlled environment (23C, 55% humidity) under
a 12 hr light-dark cycle (07:00–19:00). Food and tap water were available ad
libitum during the whole experiment. Mice were fed normal laboratory chow
(RM3, Special Diet Services, UK) throughout the experiment. Indirect calorim-
etry was performed for a period of 60 hr (Comprehensive Laboratory Animal
Monitoring System, Columbus Instruments, Columbus, OH, US). An acclima-
tization period of 24 hr prior to the start of the experiment was included. Food
intake, oxygen consumption (VO2), and carbon dioxide production ratesCell M(VCO2) were measured at intervals of 7 min. Respiratory exchange ratio
(RER) was calculated as the ratio between VCO2 and VO2. Absolute oxidation
rates for fat and carbohydrate were calculated according to Peronnet and
Massicotte (Peronnet and Massicotte, 1991). Fecal output was determined
at the end of the experiment. Fat content of the feces was analyzed using
the acid steatocrit method as described previously (Dumasy et al., 2004).
All the animal studies were approved by the animal experimentation
committees of Wageningen University; Leiden University Medical Center and
Radboud University Nijmegen Medical Centre, the Netherlands; the University
of Illinois at Chicago, Chicago, IL, USA; and St. Jude Children’s Research
Hospital, Memphis, TN, USA.IL-1b and IL-18 Measurements
IL-1b concentrations in white adipose tissue or cell culture medium were
determined using a specific radioimmunoassay as previously described
(Netea et al., 1996). IL-18 concentrations in white adipose tissue were
measured using a commercially available ELISA (Invitrogen). Bioactive IL-1
was measured using the murine thymoma cell line EL4/NOB 1 that produces
IL-2 in response to bioactive IL-1 (Netea et al., 1999). IL-2 levels were subse-
quently measured by ELISA (R&D).Cell Culture
Mouse 3T3-L1 cells and human SGBS cells were cultured and differentiated
toward adipocytes as described previously (Stienstra et al., 2008; Wabitsch
et al., 2001). Oil red O staining of cells was performed using a standard
protocol. Oil red O staining was quantified by using total photographic images
of the staining which were divided in multiple fields, and the number of positive
cells per field were counted. Two hours before insulin treatment of cells to
assess insulin sensitivity, cells were cultured in serum-free medium.Caspase-1 Activity Assay
Caspase-1 activity was measured in isolated adipocytes and total white
adipose tissue using a fluorometric assay (Biovision, CA, USA) following the
manufacturer’s instructions with slight modifications. Briefly, total adipose
tissue or isolated adipocytes were homogenized in lysis buffer and caspase-1
activity was measured by the addition of the caspase-1-specific peptide
YVAD-AFC. Cleavage of the substrate by caspase-1 releases AFC that can
subsequently be quantified using a fluorimeter. By comparing the fluores-
cence of AFC from an untreated sample with a sample treated with the specific
caspase-1 inhibitor Pralnacasan, caspase-1 activity can be determined.Isolation and Culturing of Primary Adipocytes
and White Adipose Tissue Explants
Freshly isolated mouse epididymal adipose tissue was used for the isolation of
adipocytes and stromal vascular cells. Minced adipose tissue was digested
using collagenase (Sigma-Aldrich) at a concentration of 5 mg/ml dissolved in
Dulbecco’s modified Eagle’s medium (DMEM). Tissues were incubated for
45 min at 37C and were subsequently filtered through a 250 mM nylon
mesh filter. After centrifugation, the floating cells were collected as adipocytes
and the pelleted cells as stromal vascular cells. Stromal vascular cells were
cultured and differentiated toward adipocytes using standard protocols. A
similar protocol was applied for the isolation of human adipocytes and stromal
vascular cells. For culturing of white adipose tissue explants, freshly isolated
fat was minced and directly brought into culture using DMEM supplemented
with 10% fetal calf serum. Human adipose tissue was obtained from patients
undergoing reconstructive abdominal surgery after written informed consent.Histology
Morphometry of individual fat cells was assessed using digital image analysis.
Microscopic images were digitized in 24 bit RGB (specimen level pixel size
1.28 3 1.28 um2). Recognition of fat cells was initially performed by applying
a region-growing algorithm on manually indicated seed points, and minimum
Feret diameter was calculated. Differences between groups were studied
using one-way univariate Anova. Tukey HSD post-hoc testing was applied
for multiple comparison testing.etabolism 12, 593–605, December 1, 2010 ª2010 Elsevier Inc. 603
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RNA from animal tissues was isolated using TRIzol reagent (Invitrogen)
following the manufacturer’s instructions. RNA was reverse transcribed using
the iScript cDNA Synthesis Kit (Bio-Rad Laboratories BV, Veenendaal, The
Netherlands). Real-time PCR was done with a Power Sybr Green PCR
master mix (Applied Biosystems) using a 7300 Real-Time PCR System
(Applied Biosystems). Melt curve analysis was included to assure a single
PCR product was formed. Values were corrected using the housekeeping
gene 36B4 or beta2-microglobulin (B2M). DNA was isolated from adipose
tissue and mitochondrial DNA was quantified using primers to detect
mitochondrial D loop. Results were corrected for the total amount of DNA
within samples using primer sequences to detect LPL. Primer sequences
are available upon request.Immunoblot Analysis
Immunoblotting was carried out using an ECL system (Amersham Biosci-
ences, Diegem, Belgium). Equal amounts of cell lysates as determined by
Bio-Rad Protein Assay reagent (Bio-Rad Laboratories BV) were resolved by
SDS/PAGE on a 12% polyacrylamide gel. Proteins were transferred using
the iBLOT system (Invitrogen) following the manufacturer’s instructions. The
pAKT and AKT antibody (R&D Systems), caspase-1 antibody (Santa Cruz),
and actin antibody (Sigma-Aldrich) were used at a dilution of 1:1000, and the
membranes were incubated overnight at 4C. The secondary antibodies were
used at a dilution of 1:5000. All incubations were performed in 13 Tris-buffered
saline (pH 7.5), with 0.1% Tween 20 and 5% dry milk. In the final washings, dry
milk was removed from the solution.Statistical Analysis
Statistical significant differences were calculated using a Student’s t test.
The cutoff for statistical significance was set at a p value of 0.05 or below.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at doi:10.1016/j.cmet.2010.11.011.ACKNOWLEDGMENTS
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